Calidi Biotherapeutics, Inc. (CLDI) Valuation — DCF, Graham & Comparables

Calidi Biotherapeutics, Inc. (CLDI) — Price $1.17 HealthcareBiotechnology — AMEX

Latest reported results:

Valuation dashboard for Calidi Biotherapeutics, Inc. (CLDI) with P/E N/A, P/B 0.53, EV/EBITDA 0.09 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents.

Analysis Summary

Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.

At the current price of $1.17, CLDI has negative trailing earnings (P/E not meaningful) and an ROE of -372.86%. Market capitalisation stands at $1M.

Balance sheet quality for CLDI: current ratio of 1.6. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.

Valuation Ratios

Price / Book0.53
EV / EBITDA0.09
Dividend Yield0.00%

Peer Comparison

SymbolCompanyMarket CapP/EP/BROE
CLDICalidi Biotherapeutics, Inc.0.53-372.9%
0QZU.LVertex Pharmaceuticals Incorporated$131.8B
VRTXVertex Pharmaceuticals Incorporated$130.6B29.766.4623.3%
0R2M.LRegeneron Pharmaceuticals, Inc.$84.0B
REGNRegeneron Pharmaceuticals, Inc.$79.8B18.792.5713.8%
ARGXargenx SE$61.2B36.307.4021.7%
MRNAModerna, Inc.$57.8B1.34-39.2%
RVMDRevolution Medicines, Inc.$41.7B15.96-96.4%

Price

Price$1.17
Market Cap$1M
ExchangeAMEX
CountryUS

Profitability

Return on Equity-372.86%
Return on Invested Capital-347.09%
Return on Assets-242.55%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%

Related companies: CANF · CMND · CNSP · KZIA · QLGN · SILO · SNGX

Explore sector: Healthcare · Biotechnology

More sections of CLDI: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks